Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis

Cancer Biomarkers

Volumn 3, Issue 6, 2007, Pages 315-324

  Sutton, Bobbie Collett ^a,b   Allen, Richard A ^a   Zhao, Zhizhuang Joe ^a   Dunn, S Terence ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b South Bend Medical Foundation   (United States)

Author keywords

Asymmetric PCR; Chronic myeloproliferative disorders; JAK2 mutation; Polycythemia vera

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL LABORATORY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; MELTING POINT; MOLECULAR BIOLOGY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN TARGETING; SENSITIVITY ANALYSIS; THROMBOCYTHEMIA; CHEMISTRY; GENETICS; GENOTYPE; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE;

BASE SEQUENCE; GENOTYPE; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE;

EID: 36649000540     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2007-3605     Document Type: Article

References (33)

1. K. Barratt and J.F. Mackay, Improving Real-Time PCR genotyping assays by asymmetric amplification, Journal of Clinical Microbiology 40 (2002), 1571-1572.
2. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, S. Swanton, G.S. Vassiliou, A.J. Bench, E.M. Boyd, N. Curtin, M.A. Scott and W.N. Fiber, the Cancer Genome Project, and A. R. Green, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet 365 (2005), 1054-1061.
3. O. Bock, G. Büsche, C. Koop, S. Schröter, T. Buhr and H. Kreipe, Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic mycloproliferative disorders, Journal of Molecular Diagnostics 8 (2006), 170-177.
4. P.J. Campbell and A.R. Green, The mycloproliferative disorders, The New England Journal of Medicine 355 (2006), 2452-2466.
5. P.J. Campbell, L.M. Scott, E.J. Baxter, A.J. Bench, A.R. Green and W.N. Fiber, Methods for the detection ofthe JAK2 V617F mutation in human myeloproliferative disorders, in: Methods in Molecular Medicine 125: Myeloid Leukemia: Methods and Protocols, I.-I. Iland, M. Hertzberg and P. Marlton eds, Humana Press Inc., Totowa, New Jersey, 2006, pp. 253-264.
6. C.-C. (Jeff) Chang, BCR/ABL-negative chronic myelopro-liferative disorders. JAK2 mutation and beyond, Archives of Pathology & Laboratory Medicine 130 (2006), 1123-1125.
7. M.L. Estes, Y. Ozawa, A.H. Williams, A.F. List and L. Sokol, Homozygous JAK2 V617P gain-of-function mutation is responsible for constitutive JAK2/STAT5 activation and proliferation of HEL.92.1.7 cell line, Blood (ASH Annual Meeting Abstracts) 106 (2005), Abstract 4377.
8. C. James, V. Ugo, J.-P. Le Couédic, J. Staerk, F. Delhommeau, C. Lacout, L. Garçon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, J. L. Villeval, S.N. Constantinescu, N. Casadevall and W. Vainchenker, A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera, Nature 434 (2005), 1144-1148.
9. J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J.T. Prchal, S. Verstovsek, M. Beran, E. Estey, H.M. Kantarjian and J.-P.J. Issa, JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia, Blood 106 (2005), 3370-3373.
10. A.V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A.J. Chase, F.H. Grand, H. White, C. Zoi, D. Loukopoulos, E. Terpos, E.-C. Vervessou, B. Schultheis, M. Emig, T. Ernst, E. Lengfelder, R. Hehlmann, A. Hochhaus, D. Oscier, R.T. Silver, A. Reiter and N.C.P. Cross, Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders, Blood 106 (2005), 2162-2168.
11. R. Kralovics, F. Passamonti, A.S. Buser, S.-S. Teo, R. Tiedt, J.R. Passweg, A. Tichelli, M. Cazzola and R.C. Skoda, A gain-of-function mutation of JAK2 in myeloproliferative disorders, The New England Journal of Medicine 352 (2005), 1779-1790.
12. N. Kröger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhäuser, A. Reiter, T. Zabelina, A.R. Zander and B. Fehse, Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis, Blood 109 (2007), 1316-1321.
13. M. Lay, R. Mariappan, J. Gotlib, L. Dietz, S. Sebastian, I. Schrijver and J.L. Zehnder, Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis, Journal of Molecular Diagnostics 8 (2006), 330-334.
14. R.L. Levine, M. Loriaux, B.J.P. Huntly, M.L. Loh, M. Beran, E. Stoffregen, R. Berger, J.J. Clark, S.G. Willis, K.T. Nguyen, N.J. Flores, E. Estey, N. Gattermann, S. Armstrong, A.T. Look, J.D. Griffin, O.A. Bernard, M.C. Heinrich, D.G. Gilliland, B. Druker and M.W.N. Deininger, The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia, Blood 106 (2005), 3377-3379.
15. R.L. Levine, M. Wadleigh, J. Cools, B.L. Ebert, G. Wernig, B.J.P. Huntly, T.J. Boggon, I. Wlodarska, J.J. Clark, S. Moore, J. Adelsperger, S. Koo, J. C. Lee, S. Gabriel, T. Mercher, A. D'Andrea, S. Fröhling, K. Döhner, P. Marynen, P. Vandenberghe, R.A. Mesa, A. Tefferi, J.D. Griffin, M.J. Eck, W.R. Sellers, M. Meyerson, T.R. Golub, S.J. Lee and D.G. Gilliland, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell 7 (2005), 387-397.
16. R. McClure, M. Mai and T. Lasho, Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders, Leukemia 20 (2006), Letters to the Editor, 168-171.
17. G. Murugesan, S. Aboudola, H. Szpurka, M.A. Verbic, J.P. Maciejewski, R.R. Tubbs and F.D. Hsi, Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis, American Journal of Clinical Pathology 125 (2006), 625-633.
18. V617F mutation in myeloproliferative disorders by melting curve analysis using the Light-Cycler system, Archives of Pathology & Laboratory Medicine 130 (2006), 997-1003.
19. F. Passamonti, E. Rumi, D. Pietra, M.G. Della Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, M. Lazzarino and M. Cazzola, Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders, Blood 107 (2006), 3676-3682.
20. J.A. Sanchez, K.E. Pierce, J.E. Rice and L.J. Wangh, Linear-after-the-exponential (LATE)-PCR: An advanced method of asymmetric PCRand its uses in quantitative real-time analysis, Proceedings of the National Academy of Sciences 101 (2004), 1933-1938.
21. L.M. Scott, P.J. Campbell, E.J. Baxter, T. Todd, P. Stephens, S. Edkins, R. Wooster, M.R. Stratton, P.A. Futreal and A.R. Green, The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders, Blood 106 (2005), 2920-2921.
22. P. Sidon, H. El Housni, B. Dessars and P. Heimann, The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors, Leukemia advance online publication 15 (June 2006), doi:10.1038.
23. M. Speletas, E. Katodritou, C. Daiou, E. Mandala, E. Papadakis, A. Kioumi, K. Ritis and I. Korantzis, Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders, Leukemia Research 11 (Oct. 2006), Epub ahead of print.
24. D.P. Steensma, JAK2 V617F in myeloid disorders: Molecular diagnostic techniques and their clinical utility, Journal of Molecular Diagnostics 8 (2006), 397-411.
25. D.P. Steensma, G.W. Dewald, T.L. Lasho, H.L. Powell, R.F. McClure, R.L. Levine, D.G. Gilliland and A. Tefferi, The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes, Blood 106 (2005), 1207-1209.
26. A. Tefferi and T. Barbui, bcr/abl-negative, classic myeloproliferative disorders: Diagnosis and treatment, Mayo Clinic Proceedings 80 (2005), 1220-1232.
27. V617F in polycythemia vera, Cancer 106 (2006), 631-635.
28. W. Vainchenker and S.N. Constantinescu, A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases, Hematology 2005 (2005), 195-200.
29. V617F mutation in myeloproliferative dosorders by ARMS-PCR and capillary electrophoresis, Leukemia 20 (2006), 1055-1060.
30. J.W. Vardiman, R.D. Brunning, N.L. Harris, R. Pierre, J. Thiele, M. Imbert, G. Flandrin and B. Bain, Chronic myeloproliferative diseases. in: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues, E.S. Jaffe, N.L. Harris, H. Stein and J.W. Vardiman, eds, IARC Press, Lyon, 2001, pp. 15-42.
31. J.-L. Villeval, C. James, D.F. Pisani, N. Casadevall and W. Vainchenker, New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients, Seminars in Thrombosis and Hemostasis 32 (2006), 341-351.
32. V617F: Prevalence in a large Chinese hospital population, Blood 109 (2007), 339-342.
33. R. Zhao, S. Xing, Z. Li, X. Fu, Q. Li, S.B. Krantz and Z.J. Zhao, Identification of an acquired JAK2 mutation in polycythemia vera, The Journal of Biological Chemistry 280 (2005), 22788-22792.